CG
DNLI icon

Cutler Group’s Denali Therapeutics DNLI Stock Holding History

Cutler Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$8K Hold
400
– – ﹤0.01% 1367
2023
Q4 		$8K Buy
+400
New +$7.92K ﹤0.01% 2510
2023
Q2 		– Sell
-600
Closed -$13K – 3695
2023
Q1 		$13K Sell
600
-1,650
-73% -$45.4K ﹤0.01% 2146
2022
Q4 		$62K Buy
2,250
+1,450
+181% +$43.1K 0.01% 1436
2022
Q3 		$24K Buy
800
+120
+18% +$3.9K ﹤0.01% 2466
2022
Q2 		$20K Sell
680
-620
-48% -$16.2K ﹤0.01% 2667
2022
Q1 		$41K Sell
1,300
-400
-24% -$13.8K ﹤0.01% 2418
2021
Q4 		$75K Buy
1,700
+540
+47% +$25.6K ﹤0.01% 2074
2021
Q3 		$58K Buy
+1,160
New +$65.4K ﹤0.01% 2386
2021
Q2 		– Sell
-600
Closed -$37.1K – 5801
2021
Q1 		$34K Buy
+600
New +$40.2K ﹤0.01% 2727
2020
Q3 		– Sell
-1,440
Closed -$43.4K – 4773
2020
Q2 		$34K Sell
1,440
-60
-4% -$1.41K ﹤0.01% 2019
2020
Q1 		$26K Buy
1,500
+1,000
+200% +$20.9K ﹤0.01% 2127
2019
Q4 		$8K Buy
500
+400
+400% +$6.66K ﹤0.01% 2744
2019
Q3 		$1K Hold
100
– – ﹤0.01% 3691
2019
Q2 		$2K Buy
+100
New +$2.24K ﹤0.01% 3533
2019
Q1 		– Sell
-100
Closed -$2K – 4180
2018
Q4 		$2K Buy
+100
New +$1.81K ﹤0.01% 3335

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Cutler Group's DNLI Position: Q1 2024 in Review

Cutler Group held its Denali Therapeutics (DNLI) position steady in Q1 2024 at 400 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #1367.

Cutler Group first reported a position in DNLI in Q4 2018 and has held it in 16 quarters since. The position peaked at $75K in Q4 2021. 210 funds tracked by Wall St. Rank hold DNLI as of Q1 2024.

  • Cutler Group held 400 shares of Denali Therapeutics worth $8K as of Q1 2024.
  • Cutler Group left its Denali Therapeutics share count unchanged in Q1 2024.
  • Denali Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1367 holding.
  • Cutler Group first reported a position in Denali Therapeutics in Q4 2018 and has held it in 16 quarters since.
  • Cutler Group's Denali Therapeutics position peaked at $75K in Q4 2021.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.